Brief: Acadia Pharmaceuticals Q1 EPS USD 0.1 Vs. IBES Estimate USD 0.05
08/05/2024 21:05
May 08 (Reuters) - Acadia Pharmaceuticals Q1 operating expenses USD 190.621 million. * Q1 product sales USD 205.831 million vs. IBES estimate USD 208.3 million * Q1 net income USD 16.555 million vs. IBES estimate USD 9.5 million * Q1 pretax profit USD 21.002 million vs. IBES estimate USD 10.7 million
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP